<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179777</url>
  </required_header>
  <id_info>
    <org_study_id>MCT-49395</org_study_id>
    <secondary_id>U01HD040364</secondary_id>
    <secondary_id>U01HD042444</secondary_id>
    <nct_id>NCT00179777</nct_id>
  </id_info>
  <brief_title>TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk</brief_title>
  <acronym>TRIGR</acronym>
  <official_title>TRIGR - Trial to Reduce IDDM in the Genetically at Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Congress</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Community (EC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to&#xD;
      conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The&#xD;
      TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because&#xD;
      their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to&#xD;
      breast feed their infants for as long as possible. Prior to birth, the child was randomly&#xD;
      assigned to receive one of two infant formulas, should formula be required prior to 8 months&#xD;
      of age. The study determined whether weaning to a possibly protective infant formula&#xD;
      decreases these children's chances of developing diabetes - as it does in the animal models&#xD;
      for diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula&#xD;
      will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes&#xD;
      and a first degree relative with type 1 diabetes, as it does in all relevant animal models&#xD;
      for the disease.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of&#xD;
      diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first&#xD;
      degree relative with type 1 diabetes (mother, father and/or full sibling).&#xD;
&#xD;
      I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of&#xD;
      clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree&#xD;
      relative.&#xD;
&#xD;
      A secondary aim is to determine relationships between cow's milk antibodies, a measure of&#xD;
      cow's milk exposure, and diabetes-associated auto-antibodies.&#xD;
&#xD;
      The mother of the unborn child is recruited during pregnancy. Randomization to one of two&#xD;
      infant formulas takes place before birth (after 35 weeks gestation) or immediately after&#xD;
      birth.&#xD;
&#xD;
      Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed&#xD;
      in supplementation or substitution for breast milk through 6-8 months from birth.&#xD;
&#xD;
      Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in&#xD;
      supplementation or substitution for breast milk through 6-8 months from birth.&#xD;
&#xD;
      All families were encouraged to breast feed their infants for as long as possible. The study&#xD;
      infant formula was only used if exclusive breast feeding ceases before 8 months of age.&#xD;
&#xD;
      Cord blood for genotyping was obtained at birth, or failing that from a heel prick by 7 days&#xD;
      of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes&#xD;
      remained in the intervention trial. All other subjects were withdrawn from the study.&#xD;
&#xD;
      All subjects were followed until the youngest subject turns age 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2002</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Type 1 Diabetes Mellitus</measure>
    <time_frame>12 and 18 months and annually from 2 years up to 14 years</time_frame>
    <description>Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Diabetes Associated Autoantibodies</measure>
    <time_frame>3, 6, 9, 12, 18 months and annually from 2 years up to 14 years</time_frame>
    <description>Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5156</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Hydrolysed infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrolysed infant formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonhydrolysed infant formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nonhydrolysed cow's milk based infant formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydrolysed infant formula</intervention_name>
    <description>Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigenâ„¢, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.</description>
    <arm_group_label>Hydrolysed infant formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nonhydrolysed infant formula</intervention_name>
    <description>Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.</description>
    <arm_group_label>Nonhydrolysed infant formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biological parent and/or full (not half) sibling of the newborn infant had type 1&#xD;
             diabetes as defined by the World Health Organization&#xD;
&#xD;
          -  The infant's parent or legal guardians gave signed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An older sibling of the newborn infant had been included in the TRIGR intervention&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  The parents were unwilling or unable to feed the infant cow's milk based products for&#xD;
             any reason (e.g., religious, cultural).&#xD;
&#xD;
          -  The newborn infant had a recognizable severe illness such as those due to chromosomal&#xD;
             abnormality, congenital malformation, respiratory failure needing assisted&#xD;
             ventilation, enzyme deficiencies, etc.&#xD;
&#xD;
          -  The gestational age of the newborn infant was less than 35 weeks.&#xD;
&#xD;
          -  The infant was older than 7 days at randomization.&#xD;
&#xD;
          -  Inability of the family to take part in the study (e.g. the family has no access to&#xD;
             any of the Study Centers, the family has no telephone).&#xD;
&#xD;
          -  The infant had received any infant formula other than Nutramigen prior to&#xD;
             randomization.&#xD;
&#xD;
          -  No HLA sample drawn before the age of 8 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikael Knip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Faculty of Medicine, Charles University, University Hospital Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Children's Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>00029HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus auf der Bult</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Medical University</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michele Hospital</name>
      <address>
        <city>Cagliari</city>
        <state>Sardinia</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Campus Bio-Medico of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Wroclaw</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-376</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Linkoping</name>
      <address>
        <city>Linkoping</city>
        <zip>S-58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.trigr.org</url>
    <description>TRIGR International website - Click here for more information on this study - www.TRIGR.org</description>
  </link>
  <link>
    <url>http://www.trigrnorthamerica.com</url>
    <description>TRIGR North America website - Click here for more information on this study - www.trigrnorthamerica.org</description>
  </link>
  <reference>
    <citation>Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, HÃ¤mÃ¤lÃ¤inen AM, Paronen J, RiikjÃ¤rv MA, Ormisson A, Ludvigsson J, Dosch HM, Hakulinen T, Knip M; National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005 May;48(5):829-37. Epub 2005 Apr 19. Erratum in: Diabetologia. 2005 Aug;48(8):1676. RiikjÃ¤rv, MA [added]; Ormisson, A [added]; Ludvigsson, J [added]; Dosch, HM [added]; Hakulinen, T [added]; Knip, M [added].</citation>
    <PMID>15838685</PMID>
  </reference>
  <reference>
    <citation>TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes. 2007 Jun;8(3):117-37.</citation>
    <PMID>17550422</PMID>
  </reference>
  <reference>
    <citation>Ã…kerblom HK, Knip M, Becker D, Dosch H-M, DuprÃ© J, Ilonen J, Krischer JP and the TRIGR Study Group. The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes. Immun, Endoc, Metab Agents in Med Chem 7:251-263, 2007.</citation>
  </reference>
  <results_reference>
    <citation>Writing Group for the TRIGR Study Group, Knip M, Ã…kerblom HK, Al Taji E, Becker D, Bruining J, Castano L, Danne T, de Beaufort C, Dosch HM, Dupre J, Fraser WD, Howard N, Ilonen J, Konrad D, Kordonouri O, Krischer JP, Lawson ML, Ludvigsson J, Madacsy L, Mahon JL, Ormisson A, Palmer JP, Pozzilli P, Savilahti E, Serrano-Rios M, Songini M, Taback S, Vaarala O, White NH, Virtanen SM, Wasikowa R. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial. JAMA. 2018 Jan 2;319(1):38-48. doi: 10.1001/jama.2017.19826.</citation>
    <PMID>29297078</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Helsinki</investigator_affiliation>
    <investigator_full_name>Mikael Knip</investigator_full_name>
    <investigator_title>Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Genetic Predisposition to Disease</keyword>
  <keyword>Infant Nutrition</keyword>
  <keyword>Primary Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT00179777/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2002-2007 Recruited through local clinics and obstetrics unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydrolysed Infant Formula</title>
          <description>Hydrolysed infant formula&#xD;
hydrolysed infant formula: hydrolysed infant formula</description>
        </group>
        <group group_id="P2">
          <title>Nonhydrolysed Infant Formula</title>
          <description>Nonhydrolysed infant formula&#xD;
nonhydrolysed infant formula: nonhydrolysed infant formula</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2613"/>
                <participants group_id="P2" count="2543"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1081"/>
                <participants group_id="P2" count="1078"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1532"/>
                <participants group_id="P2" count="1465"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes.</population>
      <group_list>
        <group group_id="B1">
          <title>Nonhydrolysed Infant Formula</title>
          <description>A conventional adapted cow's milk formula supplemented with 20% of the casein hydrolysate.</description>
        </group>
        <group group_id="B2">
          <title>Hydrolysed Infant Formula</title>
          <description>Hydrolysed Infant Formula missing intact cows milk proteins</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1078"/>
            <count group_id="B2" value="1081"/>
            <count group_id="B3" value="2159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1078"/>
                    <measurement group_id="B2" value="1081"/>
                    <measurement group_id="B3" value="2159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age at Randomization and Last Follow-up, years</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>At at randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at Last Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.96" lower_limit="0.07" upper_limit="15.61"/>
                    <measurement group_id="B2" value="11.93" lower_limit="0.24" upper_limit="15.29"/>
                    <measurement group_id="B3" value="11.95" lower_limit="0.07" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Sex (female, male) of the participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1021"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="562"/>
                    <measurement group_id="B2" value="576"/>
                    <measurement group_id="B3" value="1138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Ethicity, reported on the Study Registration form, information received from the parents</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="987"/>
                    <measurement group_id="B2" value="989"/>
                    <measurement group_id="B3" value="1976"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Race reported on the Study Registration form, information received form the parents</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1040"/>
                    <measurement group_id="B2" value="1034"/>
                    <measurement group_id="B3" value="2074"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Region of Enrollments by Country, information based on registration</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luxembourg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>family history of type 1 diabetes</title>
          <description>Family History of Type 1 Diabetes (mother, father or sibling had Type 1 diabetes), information received from the parents</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Only mother with type 1 diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="522"/>
                    <measurement group_id="B2" value="530"/>
                    <measurement group_id="B3" value="1052"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Only father with type 1 diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="722"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Only one sibling with type 1 diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one family member with type 1 diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Type 1 Diabetes Mellitus</title>
        <description>Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.</description>
        <time_frame>12 and 18 months and annually from 2 years up to 14 years</time_frame>
        <population>Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Nonhydrolysed Infant Formula</title>
            <description>Number of participants diagnosed with type 1 diabetes</description>
          </group>
          <group group_id="O2">
            <title>Hydrolysed Infant Formula</title>
            <description>Number of participants diagnosed with type 1 diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Type 1 Diabetes Mellitus</title>
          <description>Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.</description>
          <population>Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1078"/>
                <count group_id="O2" value="1081"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Diabetes Associated Autoantibodies</title>
        <description>Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years</description>
        <time_frame>3, 6, 9, 12, 18 months and annually from 2 years up to 14 years</time_frame>
        <population>Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Nonhydrolysed Infant Formula</title>
            <description>Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) in the nonhydrolysed infant formula</description>
          </group>
          <group group_id="O2">
            <title>Hydrolysed Infant Formula</title>
            <description>Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) in the hydrolysed infant formula</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diabetes Associated Autoantibodies</title>
          <description>Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years</description>
          <population>Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1078"/>
                <count group_id="O2" value="1081"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                    <measurement group_id="O2" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GADA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IA-2A+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nonhydrolysed Infant Formula</title>
          <description>Reported Adverse Events during the Follow-up in the Nonhydrolysed Infant Formula Group</description>
        </group>
        <group group_id="E2">
          <title>Hydrolysed Infant Formula</title>
          <description>Reported Adverse Events during the Follow-up in the Hydrolysed Infant Formula Group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1078"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="1078"/>
                <counts group_id="E2" subjects_affected="377" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle Ear Infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="1078"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="46" subjects_affected="35" subjects_at_risk="1078"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Suspected Study Formula Intolerence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1078"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1078"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Accident (Not Requiring Hospitalization)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1078"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Accident (Requiring Hospitalization)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="1078"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Event requiring inpatient hospitalization or prolongation of existing hospitalization</description>
                <counts group_id="E1" events="58" subjects_affected="47" subjects_at_risk="1078"/>
                <counts group_id="E2" events="75" subjects_affected="52" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Life-threatening event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1078"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Other Unspecified Adverse Event</sub_title>
                <counts group_id="E1" events="268" subjects_affected="190" subjects_at_risk="1078"/>
                <counts group_id="E2" events="320" subjects_affected="215" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Unspecified Infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="62" subjects_at_risk="1078"/>
                <counts group_id="E2" events="65" subjects_affected="61" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Disability/incapacity</sub_title>
                <description>Persistent or significant disability/incapacity</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1078"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1078"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="51" subjects_at_risk="1078"/>
                <counts group_id="E2" events="56" subjects_affected="46" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="1078"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Asthma, Other Forms of Allergy</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="1078"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1010" subjects_at_risk="1078"/>
                <counts group_id="E2" subjects_affected="1012" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle Ear Infection</sub_title>
                <counts group_id="E1" events="1951" subjects_affected="534" subjects_at_risk="1078"/>
                <counts group_id="E2" events="1796" subjects_affected="525" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia requiring IV glucose</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1078"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1519" subjects_affected="515" subjects_at_risk="1078"/>
                <counts group_id="E2" events="1598" subjects_affected="494" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Suspected Study Formula Intolerance</sub_title>
                <counts group_id="E1" events="73" subjects_affected="56" subjects_at_risk="1078"/>
                <counts group_id="E2" events="61" subjects_affected="49" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other, unspecified adverse event</sub_title>
                <counts group_id="E1" events="4452" subjects_affected="804" subjects_at_risk="1078"/>
                <counts group_id="E2" events="4380" subjects_affected="814" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other, unspecified infection</sub_title>
                <counts group_id="E1" events="3285" subjects_affected="765" subjects_at_risk="1078"/>
                <counts group_id="E2" events="3226" subjects_affected="740" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident, not requiring hospitalization</sub_title>
                <counts group_id="E1" events="194" subjects_affected="151" subjects_at_risk="1078"/>
                <counts group_id="E2" events="189" subjects_affected="140" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="123" subjects_affected="91" subjects_at_risk="1078"/>
                <counts group_id="E2" events="130" subjects_affected="80" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="6206" subjects_affected="772" subjects_at_risk="1078"/>
                <counts group_id="E2" events="5952" subjects_affected="754" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="119" subjects_affected="93" subjects_at_risk="1078"/>
                <counts group_id="E2" events="110" subjects_affected="91" subjects_at_risk="1081"/>
              </event>
              <event>
                <sub_title>Asthma, other forms of allergy</sub_title>
                <counts group_id="E1" events="783" subjects_affected="359" subjects_at_risk="1078"/>
                <counts group_id="E2" events="696" subjects_affected="332" subjects_at_risk="1081"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Mikael Knip</name_or_title>
      <organization>University of Helsinki</organization>
      <phone>+3582941 25222</phone>
      <email>mikael.knip@helsinki.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

